研究業績/教室業績(2015年以降)

2021年
1)Miyagi S, Watanabe T, Hara Y, Arata M, Uddin MMK, Mantoku K, Sago K, Yusuke Yanagi Y,
 Suzuki T, Masud HMAA , Kawada JI, Nakamura S, Miyake Y, Sato Y, Murata T, Kimura H.
 A STING inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis.
 Cancer Sci
2021 Oct 5.doi: 10.1111/cas.15152. Online ahead of print. PMID: 34609775.

2)
 Oka K, Morioka H, Eguchi M, Sato Y, Tetsuka N, Iguchi M, Kanematsu T, Fukano H, Hoshino Y,
  Kiyoi H, Yagi T.
Bursitis, Bacteremia, and Disseminated Infection of Mycobacteroides
 (Mycobacterium) abscessus subsp. massiliense. Intern Med. 2021 Sep 15;60(18):3041-3045.   doi:10.2169/internalmedicine.6189-20. Epub 2021 Mar 29. PMID: 33775997


3)Kimura H, Okuno Y, Sato Y, Watanabe T, Murata T. Deletion of Viral microRNAs in the
 Oncogenesis of Epstein-Barr Virus-Associated Lymphoma. Front Microbiol. 2021 Jul 8;12:
 667968. doi: 10.3389/fmicb.2021.667968. eCollection 2021. PMID: 34305835


4) Yanagi Y, Okuno Y, Narita Y, Masud HMA, Watanabe T, Sato Y, Kanda T, Kimura H, Murata T.
  RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr
  virus infection of primary B cells. Virology. 2021 Feb 21;557:44-54. doi:10.1016/j.virol.
  2021.02.004. Online ahead of print.
PMID: 33639481

5)Mabuchi S, Hijioka F, Watanabe T, Yanagi Y, Okuno Y, Masud HMA, Sato Y, Murata T, Kimura
  H. Role of Epstein-Barr virus C promoter deletion found in diffuse large B cell lymphoma.
  Cancers (Basel). 2021 Feb 1;13(3):561. doi: 10.3390/cancers13030561. PMID: 33535665  

6) Inagaki T, Sato Y, Ito, Takaki M, Okuno Y, Yaguchi M, Masud HMA, Watanabe T, Sato K,
  Iwami S, Murata T, Kimura H. Direct evidence of abortive lytic infection-mediated
  establishment of Epstein-Barr virus latency during B-cell infection. Front Microbiol., 2021
  Jan 21;11:575255. doi: 10.3389/fmicb.2020.575255. eCollection 2020. PMID: 33613459

2020年
1) Takano G, Esaki S, Goshima F, Enomoto A, Hatano Y, Ozaki H, Watanabe T, Sato Y, Kawakita
  D, Murakami S, Murata T, Nishiyama Y, Iwasaki S, Kimura H. Oncolytic activity of naturally
  attenuated herpes-simplex virus HF10 against an immunocompetent model of oral
  carcinoma.
Molecular Therapy – Oncolytics, 2020 Dec 19;20:220-227. doi:   
   10.1016/j.omto.2020.12.007. eCollection 2021 Mar 26. PMID: 33665360

2)    Sato Y, Iguchi M, Kato Y, Morioka H, Hirabayashi A, Tetsuka N, Tomita Y, Kato D, Yamada K, Kimura H, Yagi T. Number of concomitant drugs with thrombocytopenic adverse effect and the extent of resolution of inflammatory response are risk factors for thrombocytopenia in patients treated with Linezolid for more than 14 days. Nagoya J Med Sci 2020 Aug;82(3):407-414.doi:10.18999/nagims.82.3.407.PMID:33132425

3)    Esaki E, Goshima F, Ozaki H, Takano G, Hatano Y, Kawakita D, Ijichi K, Watanabe T, Sato Y, Murata T, Iwata H, Shibamoto Y, Murakami S, Nishiyama Y, Kimura H. Oncolytic activity of HF10 in head and neck squamous cell carcinomas. Cancer Gene Ther 2020 Aug;27(7-8):585-598. doi: 10.1038/s41417-019-0129-3. PMID: 31477804 

4)    Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, Ito Y, Fukuhara N, Hirose A, Takeda Y, Makita M, Endo T, Kimura SI, Ishimura M, Miura O, Ohga S, Kimura H, Fujiwara S, Arai A. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020 Jul 14;4(13):2918-2926. doi: 10.1182/bloodadvances.2020001451. PMID: 32598475 

5)    Shibata A, Ishiguro Y, Makita S, Yamaga Y, Kimura H, Akiyama M. A systemic form chronic active Epstein-Barr virus infection diagnosed from erythema nodosum-like skin lesions. Eur J Dermatol. 2020 Jun 1;30(3):314-316. doi: 10.1684/ejd.2020.3781. PMID: 32666933 

6)    Murata T, Okuno Y, Sato Y, Watanabe T, Kimura H. Oncogenesis of CAEBV Revealed: Intragenic Deletions in the Viral Genome and Leaky Expression of Lytic Genes". Rev Med Virol. 2020 Mar;30(2):e2095. doi: 10.1002/rmv.2095. PMID: 31845495 

7)    Cohen JI, Iwatsuki K, Ko YH, Kimura H, Manoli I, Ohshima K, Pittaluga S, Quintanilla-Fend L, Jaffe ES. Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. Lymphoma Leuk 2020 Apr;61(4):808-819. doi: 10.1080/10428194.2019.1699080. PMID: 31833428

8)    Watanabe T, Sato Y, Masud HMA, Takayama M, Matsuda H, Hara Y, Yanagi Y, Yoshida M, Goshima F, Murata T, Kimura H. Antitumor activity of CDK inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders. Cancer Sci 2020 Jan;111(1):279-287. doi: 10.1111/cas.14241. PMID: 31743514 


2019年

1)  Iemura T, Kondo T, Hishizawa M, Yamashita K, Kimura H, Takaori-Kondo A. NK-cell post-transplant lymphoproliferative disease with chronic active Epstein-Barr virus infection-like clinical findings. Int J Infect Dis. 2019 Nov;88:31-33. doi: 10.1016/j.ijid.2019.07.039. Epub 2019 Aug 6. PMID: 31398454

2)  Fujiwara S, Kimura H. Editorial: Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases. Frontiers Pediatr. 2019 Jul 10;7:285. doi: 10.3389/fped.2019.00285. PMID: 31355168

3)  Kawada JI, Kamiya Y, Sawada A, Iwatsuki K, Izutsu K, Torii Y, Kimura H, Ito Y. Viral DNA loads in various blood components of patients with Epstein–Barr virus-positive-T/NK cell lymphoproliferative diseases. J Infect Dis. 2019 Sep 13;220(8):1307-1311. doi: 10.1093/infdis/jiz315. PMID: 31240305

4)  Masud HMA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T. The BOLF1 Gene is Necessary for Effective Epstein-Barr Viral Infectivity. Virology. 2019 May;531:114-125. doi: 10.1016/j.virol.2019.02.015. PMID: 30856483

5)  Miyake Y, Keusch JJ, Decamps L, Ho-Xuan H, Iketani S, Gut H, Kutay U, Helenius A, Yamauchi Y. Influenza virus uses transportin 1 for vRNP debundling during cell entry. Nat Microbiol. 2019 Apr;4(4):578-586. doi: 10.1038/s41564-018-0332-2 PMID: 30692667

6)  Sato Y, Watanabe T, Suzuki C, Abe Y, Masud HMA, Inagaki T, Yoshida M, Suzuki T, Goshima F, Adachi J, Tomonaga T, Murata T, Kimura H. S-like phase CDKs stabilize the Epstein-Barr virus BDLF4 protein to temporally control late gene transcription. J Virol. 2019 Apr 3;93(8). pii: e01707-18. doi: 10.1128/JVI.01707-18. PMID: 30700607

7)  Yanagi Y, Masud HMA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T. Initial Characterization of the Epstein-Barr Virus BSRF1 Gene Product. Viruses. 2019 Mar 21;11(3). pii: E285. doi: 10.3390/v11030285. PMID: 30901892 

8)  Okuno Y, Murata Y, Sato Y, Muramatsu H, YIto Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta1 A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H. Defective Epstein-Barr virus (EBV) in chronic active EBV infection and EBV-related hematological malignancy. Nat Microbiol. 2019 Mar;4(3):404-413. doi: 10.1038/s41564-018-0334-0. PMID: 30664667 プレスリリース/解説

9)  Kimura H, Kwong YL. EBV Viral Loads in Diagnosis, Monitoring, and Response Assessment. Frontiers Oncol. 2019 Feb 12;9:62. doi: 10.3389/fonc.2019.00062. PMID: 30809508

10)Kimura H, Fujiwara S. Overview of EBV-associated T/NK-cell lymphoproliferative diseases. Frontiers Pediatr. 2019 Jan 4;6:417. doi: 10.3389/fped.2018.00417. PMID: 30662890


2018年

1)  Ichikawa T, Okuno Y, Sato Y, Goshima F, Yoshiyama H, Kanda T, Kimura H, Murata T.  Regulation of EBV Lifecycle and Cell Proliferation by Histone H3K27 Methyltransferase, EZH2, in Akata Cells. mSphere. 2018 Nov 28;3(6). pii: e00478-18. doi: 10.1128/mSphere.00478-18. PMID: 3048715

2) Kimura H. JAK inhibitors for refractory lymphoma. Oncotarget 2018, Vol. 9, (No. 68), pp:          32883-32884 doi: 10.18632/oncotarget.26054   

3) Murata T. Encyclopedia of EBV-Encoded Lytic Genes: An Update. Adv Exp Med Biol.  
  2018;1045:395-412.   doi: 10.1007/978-981-10-7230-7_18. PMID: 29896677
   

4)Watanabe D, Goshima F. Oncolytic Virotherapy by HSV. Adv Exp Med Biol. 2018;1045:63-84. doi:
   10.1007/978-981-10-7230-7_4. PMID: 29896663
 


5)Kimura H. EBV in T-/NK-Cell Tumorigenesis. Adv Exp Med Biol. 2018;1045:459-475.   
  doi:10.1007/978-981-10-7230-7_21. PMID: 29896680
 

6)Konishi N, Narita Y, Hijioka F, Masud HMAA, Sato Y, Kimura H, Murata M. BGLF2 Increases Infectivity of
  Epstein-Barr virus by Activating AP-1 upon de novo Infection. mSphere 2018 Apr 25;3(2). pii:         e00138-18. doi: 10.1128/mSphere.00138-18. PMID: 29695622
     

7)Miyake Y, Matthias P, Yamauchi Y. Purification of Unanchored Polyubiquitin Chains from Influenza Virions. Methods Mol Biol. 2018;1836:329-342. doi: 10.1007/978-1-4939-8678-1_16. PMID: 30151581

8) Matsuzawa T, Nakamura Y, Ogawa Y, Ishimaru K, Goshima F, Shimada S, Nakao A, Kawamura T.
  Differential Day-Night Outcome to HSV-2 Cutaneous Infection. J Invest Dermatol. 2018
  Jan;138(1):233-236. doi: 10.1016/j.jid.2017.07.838. PMID: 28842321

9)Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Oishi N, Choi I, Fujimaki K,
  Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D,   Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein   Barr virus positive T/NK-cell lymphoproliferative disorder: Adult patients with chronic active Epstein Barr   virus infection-like features. Haematologica. 2018 Jun;103(6):1018-1028. doi:      
  10.3324/haematol.2017.174177. PMID: 29242302


10)   
Kawada JI, Ando S, Torii Y, Ito Y, Kimura H. Antitumor effects of duvelisib on Epstein-Barr
   virus-associated lymphoma cells. Cancer Med 2018 Apr;7(4):1275-1284. doi: 10.1002/cam4. PMID:
  29522278


2017年

1)    Kimura H, Cohen JI. Chronic Active Epstein-Barr Virus Disease. Front Immunol 8:1867, 2017 doi: 10.3389/fimmu.2017.01867

2)    Yoshida M, Murata T, Ashio K, Narita Y, Watanabe T, Masud HMAA, Sato Y, Goshima F, Kimura H. Characterization of a Suppressive Cis-acting Element in the Epstein-Barr virus LMP1 Promoter. Front Microbiol 8: 2302, 2017

3)    Masud HMA, Watanabe T, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T. Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production. J Virol 91: e00975-1, 2017 doi: 10.1128/JVI.00975-17.

4)    Quintanilla-Martinez L, Ko YH, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J eds. Revised 4th ed, IARC Press, Lyon, p355-62, 2017

5)    Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, Watanabe D, Kimura H. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am J Cancer Res 7:1693-1703, 2017

6)    Yoshida M, Watanabe T, Narita Y, Sato Y, Goshima F, Kimura H, Murata T. The Epstein-Barr Virus BRRF1 Gene is Dispensable for Viral Replication in HEK293 cells and Transformation. Sci Rep 7:6044, 2017

7)    Sato Y, Ochiai S, Murata T, Kanda T, Goshima F, Kimura H. Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells. Oncotarget 8:39345-39355, 2017

8)    Washio K, Oka T, Abdalkader L, Muraoka M, Shimada A, Oda M, Sato H, Takata K, Kagami Y, Shimizu N, Seto M, Nakamura S, Kimura H, Yoshino T, Tsukahara H. Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia. Leuk Lymphoma 58: 2683-2694, 2017

9)    Watanabe T, Sakaida K, Yoshida M, Masud HMA, Sato Y, Goshima F, Kimura H, Murata T. The C-terminus of Epstein-Barr virus BRRF2 is required for its proper localization and efficient virus production. Front Microbiol 8: 125, 2017 

10)  Torii Y, Kawada JI, Murata T, Yoshiyama H, Kimura H, Ito Y. Epstein-Barr virus infection-induced inflammasome activation in human monocytes. PLoS One 12(4):e0175053, 2017

2016年
1)Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H,
 Tsurumi T, Kimura H. Induction of Epstein-Barr Virus Oncoprotein Latent Membrane Protein 1 (LMP1) by   Transcription Factors Activating Protein 2 (AP-2) and Early B Cell Factor (EBF). J Virol 90:3873-89, 2016

2) Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, Ito Y, Kimura H. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget 7:76793-76805, 2016

3) Kawano Y, Kawada JI, Kamiya Y, Suzuki M, Torii Y, Kimura H, Ito Y. Analysis of circulating human and viral microRNAs in patients with congenital cytomegalovirus infection. J Perinatol 36: 1101-1105, 2016 

4) Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Moriishi K, Nakao A, Shimada S. The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell-Mediated Antiviral Innate Immunity. J Invest Dermatol 136(6):1290-2, 2016.  

5) Kawamura Y, Miura H, Matsumoto Y, Uchida H, Kudo K, Hata T, Ito Y, Kimura H, Yoshikawa T. A case of Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis with severe cardiac complications. BMC Pediatrics 16:172, 2016 

6) Ikumi K, Ando T, Katano H, Katsuno M, Sakai Y, Yoshida M, Saida T, Kimura H, Sobue G. HSV-2-related hemophagocytic lymphohistiocytosis in a fingolimod-treated MS patient. Neurol Neuroimmunol Neuroinflamm 3(4):e247, 2016 

7) Shimomura M, Morishita H, Meguro T, Seto S, Kimura M, Hamazaki M, Hashimoto A, Sugiyama Y, Kimura H. A case of CAEBV showing features of granulomatosis with polyangiitis. Pediatr Int 58:639-42, 2016 

8) Ito Y, Suzuki M, Kawada J, Kimura H. Diagnostic values for the viral load in peripheral blood mononuclear cells of patients with chronic active Epstein-Barr virus disease. J Infect Chemother 22:268-271, 2016


2015年
1) Watanabe T, Narita Y, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T. Epstein-Barr virus BDLF4 gene
 is required for efficient expression of viral late lytic genes. J Virol 89(19):10120-4

2) Narita Y, Sugimoto A, Kawashima D, Watanabe T, Kanda T, Kimura H, Tsurumi T, Murata T. A herpesvirus specific motif of Epstein-Barr virus DNA polymerase is required for the efficient lytic genome synthesis. Sci Rep 5:11767, 2015

3) Watanabe T, Tsuruoka M, Narita Y, Katsuya R, Goshima F, Kimura H, Murata T. The Epstein-Barr virus BRRF2 gene product is involved in viral progeny production. Virology 484:33-40, 2015

4) Watanabe T, Fuse K, Takano T, Narita Y, Goshima F, Kimura H, Murata T. Roles of Epstein-Barr virus BGLF3.5 Gene and Two Upstream Open Reading Frames in Lytic Viral Replication in HEK293 Cells. Virology 483: 44–53, 2015

5) Suzuki M, Takeda T, Nakagawa H, Iwata S, Watanabe T, Siddiquey MN, Goshima F, Murata T, Kawada JI, Ito Y, Kojima S, Kimura H. The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.Front Microbiol 6:280, 2015

6) Nagata K, Nakayama Y, Higaki K, Ochi M, Kanai K, Matsushita M, Kuwamoto S, Kato M, Murakami I, Iwasaki T, Nanba E, Kimura H, Hayashi K. Reactivation of persistent Epstein—Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBVinfected B lymphocytes with TRAbs on their surface. Autoimmunity 11:1-8, 2015  

7) Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Onoda H, Yatabe Y, Ito M, Miyamura K, Nagai H, Moritani S, Sugiura I, Tsushita K, Mihara H, Ohbayashi K, Iba S, Emi N, Okamoto M, Iwata S, Kimura H, Kuzushima K, Morishima Y.  Increased T-cell responses to EBV with high viral load in patients with EBV-positive diffuse large B-cell lymphoma.Leukemia & Lymphoma 56:1072-8, 2015  

8) Coleman CB, Wohlford EM, Smith NA, King CA, Ritchie JA, Baresel PC, Kimura H, Rochford R. Epstein-Barr virus Type 2 latently infects T-cells inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol 89:2301-12, 2015  

9) Kawada J, Torii Y, Kawano Y, Suzuki M, Kamiya Y, Kotani T, Kikkawa F, Kimura H, Ito Y. Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening. J Clin Virol 65:41-5, 2015  

10) Kawano Y, Suzuki M, Kawada JI, Kimura H, Kamei H, Ohnishi Y, Ono Y, Uchida H, Ogura Y, Ito Y. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine 33:1440-5, 2015  

その他情報公開

 「RNAseq data of B cell infection: mock vs infection

 

教員業績(Staffs紹介ページの各教員名からもご覧いただけます)